D-0525-2020 Class II Terminated

Recalled by AVKARE Inc. — Pulaski, TN

FDA drug recall D-0525-2020 was initiated by AVKARE Inc. on Nov 14, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API The recall status is terminated (terminated Oct 27, 2021). Affected quantity: 104,797 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 4, 2019
Initiation Date
Nov 14, 2019
Termination Date
Oct 27, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
104,797 bottles

Product description

AVKARE Ranitidine Tablets, USP 300 mg Rx Only NDC Manufactured for: AvKARE, Inc. Pulaski, TN 38478 a) 250 tablets NDC 42291-725-25; b) 30 tablets NDC 42291-725-30

Reason for recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Distribution pattern

Nationwide.

Code information

Lots: a) 21307 Exp. 02/29/2020, 21309 Exp. 02/29/2020, 21528 Exp. 02/29/2020, 21527 Exp. 02/29/2020, 22247 Exp. 06/30/2020, 23214 Exp. 09/30/2020, 23243 Exp. 09/30/2020, 23244 Exp. 11/30/2020, 24198 Exp. 01/31/2021, 24199 Exp. 01/31/2021, 24289 Exp. 01/31/2021; b) 22291 Exp. 06/30/2020, 23215 Exp. 09/30/2020, 23776 Exp. 01/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0525-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0525-2020. Report a data issue: hello@regdatalab.com.